Stress kinase signaling in cancer: Fact or fiction?

Cancer Letters

Volumn 217, Issue 1, 2005, Pages 1-9

  Rennefahrt, Ulrike ^a   Janakiraman, Manickam ^b   Öllinger, Robert ^b   Troppmair, Jakob ^b  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Cancer; JNK; p38; Signaling; Stress kinases

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; CYCLIN D1; CYTOKINE RECEPTOR; HYPOXIA INDUCIBLE FACTOR 1; HYPOXIA INDUCIBLE FACTOR 1ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROTEIN BCL 2; PROTEIN P53; PROTEIN SERINE THREONINE KINASE; RAF PROTEIN; RAS PROTEIN; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR AP 1;

ANGIOGENESIS; AVIAN SARCOMA VIRUS; B CELL LYMPHOMA; CANCER GROWTH; CARCINOGENESIS; CELL CYCLE G2 PHASE; CELL PROLIFERATION; CHONDROSARCOMA; ENZYME ACTIVATION; ENZYME ACTIVITY; FOLLICULAR LYMPHOMA; GENE MUTATION; GLIOMA; LIVER CELL CARCINOMA; NONHUMAN; ONCOGENE; PHOSPHORYLATION; PRIORITY JOURNAL; RETROVIRUS; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR SUPPRESSOR GENE;

EID: 10444277340     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2004.08.003     Document Type: Review

References (100)

1. D. Hanahan, and R.A. Weinberg The hallmarks of cancer Cell 100 2000 57 70
2. G. Daum, I. Eisenmann-Tappe, H.W. Fries, J. Troppmair, and U.R. Rapp The ins and outs of Raf kinases Trends Biochem. Sci. 19 1994 474 480
3. R.H. Giles, J.H. van Es, and H. Clevers Caught up in a Wnt storm: Wnt signaling in cancer Biochim. Biophys. Acta 1653 2003 1 24
4. M. Pasca di Magliano, and M. Hebrok Hedgehog signalling in cancer formation and maintenance Nat. Rev. Cancer 3 2003 903 911
5. C. Luo, and P. Laaja Inhibitors of JAKs/STATs and the kinases: a possible new cluster of drugs Drug Discov. Today 9 2004 268 275
6. I. Vivanco, and C.L. Sawyers The phosphatidylinositol 3-Kinase AKT pathway in human cancer Nat. Rev. Cancer 2 2002 489 501
7. A.P. Weng, and J.C. Aster Multiple niches for Notch in cancer: context is everything Curr. Opin. Genet. Dev. 14 2004 48 54
8. U.R. Rapp, and J. Troppmair Dominant oncogenes as cancer targets: role of raf kinases and myc, two master regulators of phenotypic and genotypic stability R. Rosenthal U. Wahn H. Wolf Einfluss von Genomprojekt und Pharmacogenetics auf die Medizinische Entwicklung Symposium der Novartis Stiftung 2002 Schattauer Verlag New York 25 42
9. S. Pelengaris, T. Littlewood, M. Khan, G. Elia, and G. Evan Reversible activation of c-Myc in skin: induction of a complex neoplastic phenotype by a single oncogenic lesion Mol. Cell 3 1999 565 577
10. E. Kerkhoff, L.M. Fedorov, R. Siefken, A.O. Walter, T. Papadopoulos, and U.R. Rapp Lung-targeted expression of the c-Raf-1 kinase in transgenic mice exposes a novel oncogenic character of the wild-type protein Cell Growth Differ. 11 2000 185 190
11. W.C. Hahn, C.M. Counter, A.S. Lundberg, R.L. Beijersbergen, M.W. Brooks, and R.A. Weinberg Creation of human tumour cells with defined genetic elements Nature 400 1999 464 468
12. C.L. Sawyers Disabling Abl-perspectives on Abl kinase regulation and cancer therapeutics Cancer Cell 1 2002 13 15
13. P. Blume-Jensen, and T. Hunter Oncogenic kinase signalling Nature 411 2001 355 365
14. J. Troppmair, J.T. Bruder, H. Munoz, P.A. Lloyd, J. Kyriakis, and P. Banerjee Mitogen-activated protein kinase/extracellular signal-regulated protein kinase activation by oncogenes, serum, and 12-O-tetradecanoylphorbol-13-acetate requires Raf and is necessary for transformation J. Biol. Chem. 269 1994 7030 7035
15. M.J. Robinson, S.A. Stippec, E. Goldsmith, M.A. White, and M.H. Cobb A constitutively active and nuclear form of the MAP kinase ERK2 is sufficient for neurite outgrowth and cell transformation Curr. Biol. 8 1998 1141 1150
16. S. Cowley, H. Paterson, P. Kemp, and C.J. Marshall Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells Cell 77 1994 841 852
17. L. Chang, and M. Karin Mammalian MAP kinase signalling cascades Nature 410 2001 37 40
18. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934
19. J.M. Kyriakis, P. Banerjee, E. Nikolakaki, T. Dai, E.A. Rubie, and M.F. Ahmad The stress-activated protein kinase subfamily of c-Jun kinases Nature 369 1994 156 160
20. S. Gupta, T. Barrett, A.J. Whitmarsh, J. Cavanagh, H.K. Sluss, B. Derijard, and R.J. Davis Selective interaction of JNK protein kinase isoforms with transcription factors Eur. Mol. Biol. Org. J. 15 1996 2760 2770
21. D.D. Yang, C.Y. Kuan, A.J. Whitmarsh, M. Rincon, T.S. Zheng, and R.J. Davis Absence of excitotoxicity-induced apoptosis in the hippocampus of mice lacking the Jnk3 gene Nature 389 1997 865 870
22. Y. Fleming, C.G. Armstrong, N. Morrice, A. Paterson, M. Goedert, and P. Cohen Synergistic activation of stress-activated protein kinase 1/c-Jun N-terminal kinase (SAPK1/JNK) isoforms by mitogen-activated protein kinase kinase 4 (MKK4) and MKK7 Biochem. J. 352 Pt 1 2000 145 154
23. E. Shaulian, and M. Karin AP-1 as a regulator of cell life and death Nat. Cell. Biol. 4 2002 E131 E136
24. C. Dong, R.J. Davis, and R.A. Flavell Signaling by the JNK group of MAP kinases. c-jun N-terminal Kinase J. Clin. Immunol. 21 2001 253 257
25. C.R. Weston, and R.J. Davis The JNK signal transduction pathway Curr. Opin. Genet. Dev. 12 2002 14 21
26. P. Martin, and W. Wood Epithelial fusions in the embryo Curr. Opin. Cell Biol. 14 2002 569 574
27. T. Igaki, H. Kanda, Y. Yamamoto-Goto, H. Kanuka, E. Kuranaga, T. Aigaki, and M. Miura Eiger, a TNF superfamily ligand that triggers the Drosophila JNK pathway Eur. Mol. Biol. Org. J. 21 2002 3009 3018
28. E. Moreno, M. Yan, and K. Basler Evolution of TNF signaling mechanisms: JNK-dependent apoptosis triggered by Eiger, the Drosophila homolog of the TNF superfamily Curr. Biol. 12 2002 1263 1268
29. T. Mizuno, N. Hisamoto, T. Terada, T. Kondo, M. Adachi, and E. Nishida The Caenorhabditis elegans MAPK phosphatase VHP-1 mediates a novel JNK-like signaling pathway in stress response Eur. Mol. Biol. Org. J. (2004)
30. M. Rincon, and G. Pedraza-Alva JNK and p38 MAP kinases in CD4+ and CD8+T cells Immunol. Rev. 192 2003 131 142
31. R.J. Davis Signal transduction by the JNK group of MAP kinases Cell 103 2000 239 252
32. G. Pearson, F. Robinson, T. Beers Gibson, B.E. Xu, M. Karandikar, K. Berman, and M.H. Cobb Mitogen-activated protein (MAP) kinase pathways: regulation and physiological functions Endocr. Rev. 22 2001 153 183
33. K. Takeda, and H. Ichijo Neuronal p38 MAPK signalling: an emerging regulator of cell fate and function in the nervous system Genes Cells 7 2002 1099 1111
34. D.H. Kim, R. Feinbaum, G. Alloing, F.E. Emerson, D.A. Garsin, and H. Inoue A conserved p38 MAP kinase pathway in Caenorhabditis elegans innate immunity Science 297 2002 623 626
35. A.R. Nebreda, and A. Porras p38 MAP kinases: beyond the stress response Trends Biochem. Sci. 25 2000 257 260
36. S.A. McCarthy, M.L. Samuels, C.A. Pritchard, J.A. Abraham, and M. McMahon Rapid induction of heparin-binding epidermal growth factor/diphtheria toxin receptor expression by Raf and Ras oncogenes Genes Dev. 9 1995 1953 1964
37. Y.H. Shen, J. Godlewski, J. Zhu, P. Sathyanarayana, V. Leaner, and M.J. Birrer Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors J. Biol. Chem. 278 2003 26715 26721
38. P.K. Vogt Jun, the oncoprotein Oncogene 20 2001 2365 2377
39. W. Jochum, E. Passegue, and E.F. Wagner AP-1 in mouse development and tumorigenesis Oncogene 20 2001 2401 2412
40. A.C. Schuh, S.J. Keating, F.S. Monteclaro, P.K. Vogt, and M.L. Breitman Obligatory wounding requirement for tumorigenesis in v-jun transgenic mice Nature 346 1990 756 760
41. S. Mathas, M. Hinz, I. Anagnostopoulos, D. Krappmann, A. Lietz, and F. Jundt Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B Eur. Mol. Biol. Org. J. 21 2002 4104 4113
42. A. Lloyd, N. Yancheva, and B. Wasylyk Transformation suppressor activity of a Jun transcription factor lacking its activation domain Nature 352 1991 635 638
43. U.R. Rapp, J. Troppmair, T. Beck, and M.J. Birrer Transformation by Raf and other oncogenes renders cells differentially sensitive to growth inhibition by a dominant negative c-jun mutant Oncogene 9 1994 3493 3498
44. R. Eferl, R. Ricci, L. Kenner, R. Zenz, J.P. David, M. Rath, and E.F. Wagner Liver tumor development. c-Jun antagonizes the proapoptotic activity of p53 Cell 112 2003 181 192
45. S. Leppa, R. Saffrich, W. Ansorge, and D. Bohmann Differential regulation of c-Jun by ERK and JNK during PC12 cell differentiation Eur. Mol. Biol. Org. J. 17 1998 4404 4413
46. A.B. Raitano, J.R. Halpern, T.M. Hambuch, and C.L. Sawyers The Bcr-Abl leukemia oncogene activates Jun kinase and requires Jun for transformation Proc. Natl Acad. Sci. USA 92 1995 11746 11750
47. X. Xu, O. Heidenreich, I. Kitajima, K. McGuire, Q. Li, B. Su, and M. Nerenberg Constitutively activated JNK is associated with HTLV-1 mediated tumorigenesis Oncogene 13 1996 135 142
48. M. Dickens, J.S. Rogers, J. Cavanagh, A. Raitano, Z. Xia, and J.R. Halpern A cytoplasmic inhibitor of the JNK signal transduction pathway Science 277 1997 693 696
49. G.A. Rodrigues, M. Park, and J. Schlessinger Activation of the JNK pathway is essential for transformation by the Met oncogene Eur. Mol. Biol. Org. J. 16 1997 2634 2645
50. S. Tanaka, T. Ouchi, and H. Hanafusa Downstream of Crk adaptor signaling pathway: activation of Jun kinase by v-Crk through the guanine nucleotide exchange protein C3G Proc. Natl Acad. Sci. USA 94 1997 2356 2361
51. M.A. Antonyak, L.C. Kenyon, A.K. Godwin, D.C. James, D.R. Emlet, and I. Okamoto Elevated JNK activation contributes to the pathogenesis of human brain tumors Oncogene 21 2002 5038 5046
52. H. Tsuiki, M. Tnani, I. Okamoto, L.C. Kenyon, D.R. Emlet, and M. Holgado-Madruga Constitutively active forms of c-Jun NH2-terminal kinase are expressed in primary glial tumors Cancer Res. 63 2003 250 255
53. A. Behrens, W. Jochum, M. Sibilia, and E.F. Wagner Oncogenic transformation by ras and fos is mediated by c-Jun N-terminal phosphorylation Oncogene 19 2000 2657 2663
54. N. Chen, M. Nomura, Q.B. She, W.Y. Ma, A.M. Bode, and L. Wang Suppression of skin tumorigenesis in c-Jun NH(2)-terminal kinase-2-deficient mice Cancer Res. 61 2001 3908 3912
55. Q.B. She, N. Chen, A.M. Bode, R.A. Flavell, and Z. Dong Deficiency of c-Jun-NH(2)-terminal kinase-1 in mice enhances skin tumor development by 12-O-tetradecanoylphorbol-13-acetate Cancer Res. 62 2002 1343 1348
56. N.J. Kennedy, H.K. Sluss, S.N. Jones, D. Bar-Sagi, R.A. Flavell, and R.J. Davis Suppression of Ras-stimulated transformation by the JNK signal transduction pathway Genes Dev. 17 2003 629 637
57. U.E. Rennefahrt, B. Illert, E. Kerkhoff, J. Troppmair, and U.R. Rapp Constitutive JNK activation in NIH 3T3 fibroblasts induces a partially transformed phenotype J. Biol. Chem. 277 2002 29510 29518
58. U.E. Rennefahrt, B. Illert, A. Greiner, U.R. Rapp, and J. Troppmair Tumor induction by activated JNK occurs through deregulation of cellular growth Cancer Lett. (2004)
59. R. Sanchez-Prieto, V.J. Sanchez-Arevalo, J.M. Servitja, and J.S. Gutkind Regulation of p73 by c-Abl through the p38 MAP kinase pathway Oncogene 21 2002 974 979
60. D.V. Bulavin, S. Saito, M.C. Hollander, K. Sakaguchi, C.W. Anderson, E. Appella, and A.J. Fornace Jr. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation Eur. Mol. Biol. Org. J. 18 1999 6845 6854
61. D.V. Bulavin, O.N. Demidov, S. Saito, P. Kauraniemi, C. Phillips, and S.A. Amundson Amplification of PPM1D in human tumors abrogates p53 tumor-suppressor activity Nat. Genet. 31 2002 210 215
62. A. Porras, S. Zuluaga, E. Black, A. Valladares, A.M. Alvarez, and C. Ambrosino P38 alpha mitogen-activated protein kinase sensitizes cells to apoptosis induced by different stimuli Mol. Biol. Cell 15 2004 922 933
63. J.N. Lavoie, G. L'Allemain, A. Brunet, R. Muller, and J. Pouyssegur Cyclin D1 expression is regulated positively by the p42/p44MAPK and negatively by the p38/HOGMAPK pathway J. Biol. Chem. 271 1996 20608 20616
64. G.Y. Kim, S.E. Mercer, D.Z. Ewton, Z. Yan, K. Jin, and E. Friedman The stress-activated protein kinases p38 alpha and JNK1 stabilize p21(Cip1) by phosphorylation J. Biol. Chem. 277 2002 29792 29802
65. A.S. Yee, E.K. Paulson, M.A. McDevitt, K. Rieger-Christ, I. Summerhayes, and S.P. Berasi The HBP1 transcriptional repressor and the p38 MAP kinase: unlikely partners in G1 regulation and tumor suppression Gene 336 2004 1 13
66. J.H. Losa, C.P. Cobo, J.G. Viniegra, V.J. Sanchez-Arevalo Lobo, S. Roman y Cajal, and R. Sanchez-Prieto Role of the p38 MAPK pathway in cisplatin-based therapy Oncogene 22 2003 3998 4006
67. S. Mabuchi, M. Ohmichi, A. Kimura, Y. Ikebuchi, K. Hisamoto, and E. Arimoto-Ishida Tamoxifen inhibits cell proliferation via mitogen-activated protein kinase cascades in human ovarian cancer cell lines in a manner not dependent on the expression of estrogen receptor or the sensitivity to cisplatin Endocrinology 145 2004 1302 1313
68. K.S. Elenitoba-Johnson, S.D. Jenson, R.T. Abbott, R.A. Palais, S.D. Bohling, and Z. Lin Involvement of multiple signaling pathways in follicular lymphoma transformation: p38-mitogen-activated protein kinase as a target for therapy Proc. Natl Acad. Sci. USA 100 2003 7259 7264
69. D. Halawani, R. Mondeh, L.A. Stanton, and F. Beier p38 MAP kinase signaling is necessary for rat chondrosarcoma cell proliferation Oncogene 23 2004 3726 3731
70. D.H. Teng, W.L. Perry 3rd, J.K. Hogan, M. Baumgard, R. Bell, and S. Berry Human mitogen-activated protein kinase kinase 4 as a candidate tumor suppressor Cancer Res. 57 1997 4177 4182
71. L. Wang, Y. Pan, and J.L. Dai Evidence of MKK4 pro-oncogenic activity in breast and pancreatic tumors Oncogene (2004)
72. W. Lin, H.W. Kao, D. Robinson, H.J. Kung, C.W. Wu, and H.C. Chen Tyrosine kinases and gastric cancer Oncogene 19 2000 5680 5689
73. M. Schreiber, A. Kolbus, F. Piu, A. Szabowski, U. Mohle-Steinlein, and J. Tian Control of cell cycle progression by c-Jun is p53 dependent Genes Dev. 13 1999 607 619
74. R. Johnson, B. Spiegelman, D. Hanahan, and R. Wisdom Cellular transformation and malignancy induced by ras require c-jun Mol. Cell Biol. 16 1996 4504 4511
75. F. Hilberg, A. Aguzzi, N. Howells, and E.F. Wagner c-jun is essential for normal mouse development and hepatogenesis Nature 365 1993 179 181
76. P. Hess, G. Pihan, C.L. Sawyers, R.A. Flavell, and R.J. Davis Survival signaling mediated by c-Jun NH(2)-terminal kinase in transformed B lymphoblasts Nat. Genet. 32 2002 201 205
77. C. Yu, Y. Minemoto, J. Zhang, J. Liu, F. Tang, and T.N. Bui JNK Suppresses apoptosis via phosphorylation of the proapoptotic Bcl-2 family protein BAD Mol. Cell 13 2004 329 340
78. D.P. Brazil, J. Park, and B.A. Hemmings PKB binding proteins. Getting in on the Akt Cell 111 2002 293 303
79. H.G. Wang, U.R. Rapp, and J.C. Reed Bcl-2 targets the protein kinase Raf-1 to mitochondria Cell 87 1996 629 638
80. Y.R. Chen, and T.H. Tan The c-Jun N-terminal kinase pathway and apoptotic signaling (review) Int. J. Oncol. 16 2000 651 662
81. T. Wada, N. Joza, H.Y. Cheng, T. Sasaki, I. Kozieradzki, and K. Bachmaier MKK7 couples stress signalling to G2/M cell-cycle progression and cellular senescence Nat. Cell Biol. 6 2004 215 226
82. M. Kunz, S. Ibrahim, D. Koczan, H.J. Thiesen, H.J. Kohler, and T. Acker Activation of c-Jun NH2-terminal kinase/stress-activated protein kinase (JNK/SAPK) is critical for hypoxia-induced apoptosis of human malignant melanoma Cell Growth Differ. 12 2001 137 145
83. K.R. Laderoute, H.L. Mendonca, J.M. Calaoagan, A.M. Knapp, A.J. Giaccia, and P.J. Stork Mitogen-activated protein kinase phosphatase-1 (MKP-1) expression is induced by low oxygen conditions found in solid tumor microenvironments. A candidate MKP for the inactivation of hypoxia-inducible stress-activated protein kinase/c-Jun N-terminal protein kinase activity J. Biol. Chem. 274 1999 12890 12897
84. R. Kerbel, and J. Folkman Clinical translation of angiogenesis inhibitors Nat. Rev. Cancer 2 2002 727 739
85. A. Alfranca, M.D. Gutierrez, A. Vara, J. Aragones, F. Vidal, and M.O. Landazuri c-Jun and hypoxia-inducible factor 1 functionally cooperate in hypoxia-induced gene transcription Mol. Cell Biol. 22 2002 12 22
86. Z.Y. Liu, R.K. Ganju, J.F. Wang, K. Schweitzer, B. Weksler, S. Avraham, and J.E. Groopman Characterization of signal transduction pathways in human bone marrow endothelial cells Blood 90 1997 2253 2259
87. S. Rousseau, F. Houle, J. Landry, and J. Huot p38 MAP kinase activation by vascular endothelial growth factor mediates actin reorganization and cell migration in human endothelial cells Oncogene 15 1997 2169 2177
88. G. Pages, E. Berra, J. Milanini, A.P. Levy, and J. Pouyssegur Stress-activated protein kinases (JNK and p38/HOG) are essential for vascular endothelial growth factor mRNA stability J. Biol. Chem. 275 2000 26484 26491
89. G. Zhang, C.R. Dass, E. Sumithran, N. Di Girolamo, L.Q. Sun, and L.M. Khachigian Effect of deoxyribozymes targeting c-Jun on solid tumor growth and angiogenesis in rodents J. Natl Cancer Inst. 96 2004 683 696
90. A. Abdollahi, P. Hahnfeldt, C. Maercker, H.J. Grone, J. Debus, and W. Ansorge Endostatin's antiangiogenic signaling network Mol. Cell 13 2004 649 663
91. J. Fang, Y. Shing, D. Wiederschain, L. Yan, C. Butterfield, and G. Jackson Matrix metalloproteinase-2 is required for the switch to the angiogenic phenotype in a tumor model Proc. Natl Acad. Sci. USA 97 2000 3884 3889
92. S. Aznar, P. Fernandez-Valeron, C. Espina, and J.C. Lacal Rho GTPases: potential candidates for anticancer therapy Cancer Lett. 206 2004 181 191
93. D. Hagemann, J. Troppmair, and U.R. Rapp Cot protooncoprotein activates the dual specificity kinases MEK-1 and SEK-1 and induces differentiation of PC12 cells Oncogene 18 1999 1391 1400
94. J. Hartkamp, J. Troppmair, and U.R. Rapp The JNK/SAPK activator mixed lineage kinase 3 (MLK3) transforms NIH 3T3 cells in a MEK-dependent fashion Cancer Res. 59 1999 2195 2202
95. J. Troppmair, J. Hartkamp, and U.R. Rapp Activation of NF-kappa B by oncogenic Raf in HEK 293 cells occurs through autocrine recruitment of the stress kinase cascade Oncogene 17 1998 685 690
96. B. Baumann, C.K. Weber, J. Troppmair, S. Whiteside, A. Israel, U.R. Rapp, and T. Wirth Raf induces NF-kappaB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation Proc. Natl Acad. Sci. USA 97 2000 4615 4620
97. A. von Gise, P. Lorenz, C. Wellbrock, B. Hemmings, F. Berberich-Siebelt, U.R. Rapp, and J. Troppmair Apoptosis suppression by Raf-1 and MEK1 requires MEK- and phosphatidylinositol 3-kinase-dependent signals Mol. Cell Biol. 21 2001 2324 2336
98. H. Davies, G.R. Bignell, C. Cox, P. Stephens, S. Edkins, and S. Clegg Mutations of the BRAF gene in human cancer Nature 417 2002 949 954
99. J. Downward Ras signalling and apoptosis Curr. Opin. Genet. Dev. 8 1998 49 54
100. E. Kerkhoff, and U.R. Rapp High-intensity Raf signals convert mitotic cell cycling into cellular growth Cancer Res. 58 1998 1636 1640